Dear diary. Well another month has passed and ugne has now hit a new high of $3.54 a share. In approximately three weeks the company will file its 10q for the Sept 05 quarter and we will see revenues for Fortical , its nasal calcitonin product, which was approved midway thru the quarter. I expect the stock to run up to the mid $4 level prior to the announcement since I hear rumors that sales are going better than expected as people sithch from the more expensive and less pure form marketed by Novartis known as Miacalcin. After that, I am looking foward to upper price movement as the company approaches relisting on Nasdaq. Still olong and strong but I wll not be averse to taking some money off the table during the next run-up. It sure is lonely here at the top.
News 
Market Data 
Discover 
